CDK4/6 inhibitors for breast cancer on AARP Medicare Rx Preferred from UHC (S5820-034)
Ibrance, Kisqali and Verzenio, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), American Samoa
- Premium
- $0.00/month
- Deductible
- $615.00
3 of 3 CDK4/6 inhibitors are covered on this plan. All 3 require prior authorization.
- from $5,052.43Tier 5
- from $2,856.09Tier 5
- $4,853.22Tier 5
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.